Around 46,000 people are diagnosed with lung cancer every year in Britain, according to Cancer Research UK.
And although 89% of cases are preventable, lung cancer accounts for roughly 36,000 deaths a year.
The lungs are part of a complex apparatus, expanding and relaxing thousands of times each day to bring in oxygen and expel carbon dioxide.
Smoking is the main avoidable risk factor for lung cancer, linked to an estimated 86% of cases in the UK.
Oncimmune (LON:ONC) is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 155,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.
